Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'HIGH-DOSE VERAPAMIL' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 28 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Gaynor, ER; Unger, JM; Miller, TP; Grogan, TM; White, LA; Mills, GM; Balcerzak, SP; Varterasian, M; LeBlanc, M; Fisher, RI
      Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: A Southwest Oncology Group study

      JOURNAL OF CLINICAL ONCOLOGY
    2. Oldham, RK; Reid, WK; Barnett, D
      Phase I study of CBT-1 (TM) and Taxol((R)) in patients with Taxol((R)) resistant cancers

      CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
    3. Belpomme, D; Gauthier, S; Pujade-Lauraine, E; Facchini, T; Goudier, MJ; Krakowski, I; Netter-Pinon, G; Frenay, M; Gousset, C; Marie, FN; Benmiloud, M; Sturtz, F
      Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma

      ANNALS OF ONCOLOGY
    4. VANDEVRIE W; MARQUET RL; STOTER G; DEBRUIJN EA; EGGERMONT AMM
      IN-VIVO MODEL SYSTEMS IN P-GLYCOPROTEIN-MEDIATED MULTIDRUG-RESISTANCE

      Critical reviews in clinical laboratory sciences
    5. FERRY DR
      TESTING THE ROLE OF P-GLYCOPROTEIN EXPRESSION IN CLINICAL-TRIALS - APPLYING PHARMACOLOGICAL PRINCIPLES AND BEST METHODS FOR DETECTION TOGETHER WITH GOOD CLINICAL-TRIALS METHODOLOGY

      International journal of clinical pharmacology and therapeutics
    6. LEHNERT M; MROSS K; SCHUELLER J; THUERLIMANN B; KROEGER N; KUPPER H
      PHASE-II TRIAL OF DEXVERAPAMIL AND EPIRUBICIN IN PATIENTS WITH NONRESPONSIVE METASTATIC BREAST-CANCER

      British Journal of Cancer
    7. PINKERTON CR
      MULTIDRUG-RESISTANCE IN CHILDHOOD SOLID TUMORS

      International journal of pediatric hematology/oncology
    8. LEHNERT M; DEGIULI R; TWENTYMAN PR
      SENSITIVE AND RAPID BIOASSAY FOR ANALYSIS OF P-GLYCOPROTEIN-INHIBITING ACTIVITY OF CHEMOSENSITIZERS IN PATIENT

      Clinical cancer research
    9. FERRY DR; TRAUNECKER H; KERR DJ
      CLINICAL-TRIALS OF P-GLYCOPROTEIN REVERSAL IN SOLID TUMORS

      European journal of cancer
    10. LEHNERT M; DEGIULI R; KUNKE K; EMERSON S; DALTON WS; SALMON SE
      SERUM CAN INHIBIT REVERSAL OF MULTIDRUG-RESISTANCE BY CHEMOSENSITIZERS

      European journal of cancer
    11. CHEN G; TEICHER BA; FREI E
      DIFFERENTIAL INTERACTIONS OF PGP INHIBITOR THALIBLASTINE WITH ADRIAMYCIN, ETOPOSIDE, TAXOL AND ANTHRAPYRAZOLE CI941 IN SENSITIVE AND MULTIDRUG-RESISTANT HUMAN MCF-7 BREAST-CANCER CELLS

      Anticancer research
    12. LIU Z; LHEUREUX F; POULIOT JF; HECKEL A; BAMBERGER U; GEORGES E
      BIBW22 BS, POTENT MULTIDRUG RESISTANCE-REVERSING AGENT, BINDS DIRECTLY TO P-GLYCOPROTEIN AND ACCUMULATES IN DRUG-RESISTANT CELLS

      Molecular pharmacology
    13. TAKESHITA H; GEBHARDT MC; SPRINGFIELD DS; KUSUZAKI K; MANKIN HJ
      EXPERIMENTAL-MODELS FOR THE STUDY OF DRUG-RESISTANCE IN OSTEOSARCOMA - P-GLYCOPROTEIN-POSITIVE, MURINE OSTEOSARCOMA CELL-LINES

      Journal of bone and joint surgery. American volume
    14. DEMMER A; DUNN T; HOOF T; KUBESCH P; TUMMLER B
      COMPETITIVE-INHIBITION OF PHOTOAFFINITY-LABELING OF P-GLYCOPROTEIN BYANTICANCER DRUGS AND MODULATORS INCLUDING S9788

      European journal of pharmacology
    15. BELLAMY WT; ODELEYE A; HUIZENGA E; DALTON WS; WEINSTEIN RS; GROGAN TM
      SEVERE COMBINED IMMUNODEFICIENCY (SCID) MOUSE MODELING OF P-GLYCOPROTEIN CHEMOSENSITIZATION IN MULTIDRUG-RESISTANT HUMAN MYELOMA XENOGRAFTS

      Clinical cancer research
    16. SONNEVELD P
      MODULATION OF MULTIDRUG-RESISTANCE IN MULTIPLE-MYELOMA

      Bailliere's clinical haematology
    17. MOORE AS; LEVEILLE CR; REIMANN KA; SHU H; ARIAS IM
      THE EXPRESSION OF P-GLYCOPROTEIN IN CANINE LYMPHOMA AND ITS ASSOCIATION WITH MULTIDRUG-RESISTANCE

      Cancer investigation
    18. COWIE FJ; PINKERTON CR; PHILLIPS M; DICK G; JUDSON I; MCCARTHY PT; FLANAGAN RJ
      CONTINUOUS-INFUSION VERAPAMIL WITH ETOPOSIDE IN RELAPSED OR RESISTANTPEDIATRIC CANCERS

      British Journal of Cancer
    19. LEHNERT M
      REVERSAL OF P-GLYCOPROTEIN-ASSOCIATED MULTIDRUG-RESISTANCE - FROM BENCH TO BEDSIDE

      Onkologie
    20. HILL BT; HOSKING LK
      DIFFERENTIAL EFFECTIVENESS OF A RANGE OF NOVEL DRUG-RESISTANCE MODULATORS, RELATIVE TO VERAPAMIL, IN INFLUENCING VINBLASTINE OR TENIPOSIDE CYTOTOXICITY IN HUMAN LYMPHOBLASTOID CCRF-CEM SUBLINES EXPRESSING CLASSIC OR ATYPICAL MULTIDRUG-RESISTANCE

      Cancer chemotherapy and pharmacology
    21. CROSTA L; CANDILORO V; MELI M; TOLOMEO M; RAUSA L; DUSONCHET L
      LACIDIPINE AND JOSAMYCIN - 2 NEW MULTIDRUG-RESISTANCE MODULATORS

      Anticancer research
    22. FRIDBORG H; LARSSON R; JUHLIN C; RASTAD J; AKERSTROM G; BACKLIN K; NYGREN P
      P-GLYCOPROTEIN EXPRESSION AND ACTIVITY OF RESISTANCE MODIFYING AGENTSIN PRIMARY CULTURES OF HUMAN RENAL AND ADRENOCORTICAL CARCINOMA-CELLS

      Anticancer research
    23. POMMERENKE E; MATTERN J; VOLM M
      MODULATION OF DOXORUBICIN-TOXICITY BY TAMOXIFEN IN MULTIDRUG-RESISTANT TUMOR-CELLS IN-VITRO AND IN-VIVO

      Journal of cancer research and clinical oncology
    24. RAMIREZ LH; MUNCK JN; ZHAO ZX; BOGNEL C; RICARD M; ARDOUIN P; ROUGIER P; GOUYETTE A
      VERAPAMIL-REVERSING CONCENTRATIONS INDUCE BLOOD-FLOW CHANGES THAT COULD COUNTERACT IN-VIVO THE MDR-1-MODULATING EFFECTS

      Cancer
    25. FRIDBORG H; JONSSON B; NYGREN P; CSOKA K; NILSSON K; OBERG G; KRISTENSEN J; BERGH J; THOLANDER B; OLSEN L; JAKOBSON A; LARSSON R
      ACTIVITY OF CYCLOSPORINES AS RESISTANCE MODIFIERS IN PRIMARY CULTURESOF HUMAN HEMATOLOGICAL AND SOLID TUMORS

      British Journal of Cancer
    26. LIST AF; SPIER C; GREER J; WOLFF S; HUTTER J; DORR R; SALMON S; FUTSCHER B; BAIER M; DALTON W
      PHASE-I II TRIAL OF CYCLOSPORINE AS A CHEMOTHERAPY-RESISTANCE MODIFIER IN ACUTE-LEUKEMIA/

      Journal of clinical oncology
    27. HILL BT; VANDERGRAAF WTA; HOSKING LK; DEVRIES EGE; MULDER NH; WHELAN RDH
      EVALUATION OF S9788 AS A POTENTIAL MODULATOR OF DRUG-RESISTANCE AGAINST HUMAN TUMOR SUBLINES EXPRESSING DIFFERING RESISTANCE MECHANISMS IN-VITRO

      International journal of cancer
    28. WIGLER PW; PATTERSON FK
      INHIBITION OF THE MULTIDRUG-RESISTANCE EFFLUX PUMP

      Biochimica et biophysica acta


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/01/21 alle ore 07:19:27